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Abstract
Objective
Although impairment in pancreatic insulin secretion is known to precede the clinical diagno-
sis of type 2 diabetes by up to a decade, fasting blood glucose concentration only rises
abnormally once the impairment reaches a critical threshold. Despite its centrality to the
pathogenesis of type 2 diabetes, the pancreas is the least studied organ due to its inacces-
sible anatomical position. Previous ultrasound and CT studies have suggested a possible
decrease in pancreatic volume in type 2 diabetes. However, ultrasound techniques are rela-
tively insensitive while CT uses ionizing radiation, making these modalities unsuitable for
precise, longitudinal studies designed to explore the underlying mechanisms of type 2 dia-
betes. Hence there is a need to develop a non-invasive, safe and precise method to quanti-
tate pancreas volume.
Methods
We developed and applied magnetic resonance imaging at 3.0T to obtain balanced turbo
field echo (BTFE) structural images of the pancreas, together with 3-point Dixon images to
quantify pancreatic triglyceride content. Pancreas volume, morphology and triglyceride con-
tent was quantified in a group of 41 subjects with well-controlled type 2 diabetes (HbA1c
7.6%) taking only metformin (duration of T2DM 5.7±0.7years), and a control group of 14 nor-
mal glucose tolerance subjects matched for age, weight and sex.
Results
The mean pancreatic volume was found to be 33% less in type 2 diabetes than in normal
glucose tolerant subjects (55.5±2.8 vs. 82.6±4.8cm3; p<0.0001). Pancreas volume was
positively correlated with HOMA-β in the type 2 diabetes subjects (r = 0.31; p = 0.03)
and controls (r = 0.46; p = 0.05) considered separately; and in the whole population studied
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(r = 0.37; p = 0.003). In type 2 diabetes, the pancreas was typically involuted with a serrated
border. Pancreatic triglyceride content was 23% greater (5.4±0.3 vs. 4.4±0.4%; p = 0.02) in
the type 2 diabetes group.
Conclusion
This study describes for the first time gross abnormalities of the pancreas in early type 2 dia-
betes and quantifies the decrease in pancreas size, the irregular morphology and increase
in fat content.
Introduction
Type 2 diabetes (T2DM) is caused by a combination of insulin resistance and decreased beta
cell function [1, 2]. However, blood glucose levels do not rise unless pancreatic insulin secreto-
ry function has declined by approximately 50%, and the subsequent gradual deterioration of
blood glucose control is related solely to declining beta cell competence [3–5]. Despite this, the
pancreas remains the least studied organ in T2DM. This is principally a result of the inaccessi-
ble anatomical position of the organ and a lack of validated methods with which to undertake
longitudinal studies. Although direct imaging of human beta cells is not yet possible, advanced
magnetic resonance techniques to quantitate structure and chemical composition offer the pos-
sibility of defining the evolving pathophysiology within the pancreas in T2DM.
Three basic aspects of the pancreas may be of relevance to the development of T2DM.
Firstly, the total volume of the pancreas must be considered given the known decrease in func-
tional beta cell number as T2DM progresses [6, 7]. In T2DM, studies using ultrasound or CT
have suggested a 7–22% decrease in pancreas volume [8–10]. Secondly, there has been no de-
scription of the overall appearance of the pancreas in T2DM. There is marked variation of pan-
creatic morphology in the general population, with a more serrated boundary of the pancreas
generally ascribed to ageing [11–13]. Thirdly, the fat content of the pancreas has been reported
to be related to beta cell function [14, 15]. However, measurement of pancreas fat using mag-
netic resonance spectroscopy has been questioned [16], and to avoid possible inclusion of sig-
nal from surrounding adipose tissue we developed an imaging-based method of high precision
[17]. Using this method during rapid weight loss, the pancreas fat content has been shown to
decrease over the same time course as return of normal insulin secretory capacity [17]. That
longitudinal study was designed to evaluate the mechanisms underlying the return to normal
glucose control during a very low calorie diet and was not large enough to quantitate precisely
the difference in pancreatic volume and morphology between T2DM and age, weight and sex
matched non-diabetic controls.
The present study was designed to define volume, morphology and fat content of the pan-
creas in a large group of individuals with T2DM.
Methods
Subjects
Forty-four subjects with well-controlled T2DM, (HbA1c 7.6%) on metformin alone were re-
cruited. This group was selected in view of the natural history of T2DM showing gradual need
for additional oral agents with 50% requiring insulin therapy by 10 years after diagnosis [18],
The mean duration of this group of T2DM with early stage disease thus defined was 5.7±0.7
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years. A group of 14 normal glucose tolerance (NGT) subjects matched for age, weight and sex
and with no first-degree family history of diabetes was studied to allow comparison. NGT was
demonstrated in all control subjects by 75g oral glucose tolerance test (mean fasting plasma
glucose 5.3mmol/l; 2h 5.5mmol/l). The clinical and metabolic characteristics are shown in
Table 1.
Protocol
All subjects underwent metabolic and anthropometric characterisation prior to the magnetic res-
onance (MR) study. As the T2DM subjects subsequently took part in a randomized study of vil-
dagliptin or placebo (n = 20 and n = 19 respectively; 2 did not complete due to unrelated medical
problems), the opportunity was taken to re-study after 6 months of either vildagliptin plus met-
formin therapy or continued metformin therapy plus placebo. The outcome of that study and the
liver triglyceride results shown (registered on ClinicalTrials.gov—NCT01356381) have been re-
ported separately [19]. The study was approved by the Newcastle and North Tyneside 2 Research
Ethics Committee (reference 13/NE/0208) and all subjects gave written consent.
Pancreas volume quantification
All MR studies were performed on a Philips 3.0T Achieva scanner with a 6-channel cardiac
surface coil used for signal detection (Philips Healthcare, Best, The Netherlands). A non-inva-
sive magnetic resonance method was developed to quantify pancreas volume using balanced
turbo field echo (BTFE) structural images. BTFE images contain a mix of T1 and T2 contrast,
which distinguishes high signal intensity from vessels and visceral fat with lower intensity sig-
nals from the pancreas. It can therefore be used to clearly delineate the boundaries of the pan-
creas from the adjacent structures, including the surrounding visceral fat, the splenic vein, the
superior mesenteric vessels, the inferior vena cava and the duodenum. Twelve axial sections of
5mm thickness were imaged during an eight second breath hold (repetition time/echo time/
flip angle = 3.1ms/1.6ms/40°, field of view 400-480x300mm according to patient size, zero-
filled to give resolution 1.39mm x 1.40mm, turbo factor 95, parallel imaging factor 2, band-
width 1156 Hz per pixel) The polygon ROI tool in the freely-available imaging software Image
J [20] was used to delineate the pancreatic tissue in each section. Integration over all the sec-
tions containing tissue allows us to obtain the total pancreas volume in cm3.
Table 1. Anthropometry andmetabolic characteristics of the Type 2 diabetes and Control groups.
Type 2 diabetes (n = 41) Controls (n = 14) p value
Weight (kg) 87.2±2.0 86.7±3.7 0.81
BMI (kg/m2) 30.3±0.5 29.6±1.0 0.67
Body fat (%) 31.6±1.2 27.9±2.6 0.11
Waist/Hip ratio (-) 0.95±0.01 0.90±0.02 0.02
Age (years) 61.8±1.0 59.0±2.2 0.10
Fasting plasma glucose (mmol/l) 7.9±0.5 5.1±0.1 <0.0001
Fasting plasma insulin (mU/L) 13.3±1.3 7.9±0.9 0.002
HOMA-β (%) 72±7.1 97.3.0 ± 9.5 0.01
HOMA-IR (μU/mol/L3) 4.7±0.4 1.9 ± 0.2 0.02
HbA1c (%) 6.4±0.1 -
Duration of diabetes (years) 5.7±0.7 -
Data are shown as mean ± SEM
doi:10.1371/journal.pone.0126825.t001
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A pancreas volume index, defined as the pancreas volume in cm3 divided by the body sur-
face area calculated by the method of Dubois and Dubois [21] was used to examine possible ef-
fects of different anthropometry on observed measurements [22]. The ratio of the pancreas
volume to the waist circumference (in cm3/cm) was also calculated to evaluate the data cor-
rected for potential excess visceral fat in T2DM subjects.
A Bland-Altman analysis was carried out to define repeatability and reproducibility of the
pancreas volume measurement, with independent interobserver assessment of pancreas vol-
ume performed by two trained analysts (MM and KP). A subset of 20 randomly selected mea-
surements were analysed twice by KP to define intraobserver statistics.
Morphology
The anterior border of the pancreas was observed to be particularly variable in respect of degree
of smoothness or irregularity. A five point semi-quantitative scale of irregularity (1 = most ir-
regular, 5 = least irregular) with standardized outlines was used to score all pancreas scans,
blind to T2DM/NGT status. Two observers (MM, RT) agreed the score for each pancreas
in consensus.
Pancreas and liver triglyceride quantification
Pancreas and liver triglyceride content were measured using the 3-point Dixon method [23]
where three gradient-echo scans are acquired with adjacent out-of-phase and in-phase echoes
(repetition time /echo times/averages/flip angle = 50ms/3.45, 4.60, 5.75ms/1/5°, bandwidth
435Hz/pixel). The fields-of-view and reconstructed resolutions were prescribed as per the
BTFE sequence. 12 sections of 10mm thickness were used to image the liver, and 12 sections of
5mm thickness to image the pancreas, during four 17-second breath-holds. CustomMATLAB
software was used to separate the fat and water contributions of the MRI and construct fat frac-
tion maps. The polygon tool in the imaging software Image J [20] was used to define regions of
interest within the homogenous pancreas parenchyma on both water images on three central
sections of pancreatic tissue. For the liver, regions of interest on five homogeneous sections
within the right lobe of the liver were evaluated, avoiding the gallbladder, large vessels and sur-
rounding visceral tissue. The triglyceride content in the images was expressed as a percentage
of the total signal from fat and water. The measurements from the defined sections were
averaged.
Body composition and anthropometry
A bioelectrical impedance device (Bodystat 1500, Bodystat Ltd, Douglas, UK) was used to mea-
sure percentage body fat. Waist hip circumference was measured with a tape measure with sub-
jects in a relaxed standing position. The waist was defined as the mid-point between the lower
edge of the ribcage superiorly and the anterior superior iliac spine inferiorly. The hip circum-
ference was taken to be at the level of the greater trochanter.
Metabolite and hormone assays
The plasma glucose concentrations were measured with a Yellow Springs glucose analyser
(YSI, Ohio, USA). HbA1c was measured by high performance liquid chromatography (Bio-
rad). Plasma insulin concentrations were measured with Dako Insulin enzyme linked immu-
noabsorbent assay (DAKO; Denmark) using a spectrophotometric analyser. An estimate of
beta cell function (HOMA-β) was calculated from the fasting plasma glucose and insulin
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concentrations according to the homeostatic model of Matthews et al. [24], where HOMA-β =
[20 x insulin concn (mU/L)]/[glucose concn (mmol/L)].
Data analysis
Data are expressed as mean±SEM. Statistics were performed using Graphpad Prism 6.0d soft-
ware). The Bland-Altman statistic was used to examine inter- and intra-observer repeatability
and reproducibility [25]. Student's two-tailed paired t-test or the Mann-Whitney test, depend-
ing upon normality of data distribution, was used to compare within group and between group
changes at different time points. Spearman correlation was used to assess relationship between
variables. The distribution of the pancreas outline scores was compared by the Mann-Whitney
test. A significance level of p< 0.05 was adopted.
Results
Pancreas volume
Mean pancreas volume was 33% smaller in T2DM compared with NGT (55.5±2.8 vs.
82.6±4.8cm3; p<0.0001)(Fig 1). In T2DM, pancreas volume ranged from 20.8 to 99.7 cm3; and
in NGT from 60.1 to 124.2 cm3. Expression of the data as pancreas volume index did not
change the extent of difference between the groups (33%; 27.8±1.3 vs. 41.7±2.5cm3/m2;
p<0.0001). When the data were expressed as ratio of pancreas volume to waist circumference,
there was a 38% decrease in this ratio in T2DM subjects (0.53±0.03 cm3/cm vs. 0.85±0.06 cm3/
cm; p<0.0001).
There was a positive correlation between HOMA-β and pancreas volume in the T2DM
group (r = 0.31; p = 0.03), the NGT group (r = 0.46; p = 0.05), and in the whole population
studied (r = 0.37; p = 0.003) (Fig 2A–2C). Pancreas volume was inversely proportional to age in
those under 60 years both in T2DM (n = 7; r = -0.56; p = 0.02) and in NGT (n = 6; r = -0.66;
p = 0.09) and did not correlate with the duration of type 2 diabetes (r = -0.15; p = 0.19).
Fig 1. Mean pancreas volume in the type 2 diabetes and control groups (error bars show standard
error of the mean). Pancreas volume was decreased by 33% (p<0.001 by Mann- Whitney U test).
doi:10.1371/journal.pone.0126825.g001
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Fig 2. Relationships between HOMA-β (%) and pancreas volume (cm3) in T2DM group (panel a),
control group (panel b) and all subjects combined (panel c). In each case there was a positive correlation
between pancreas volume and insulin secretion (Spearman test).
doi:10.1371/journal.pone.0126825.g002
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Pancreas volume remained constant over 6 months in both those T2DM subjects treated
with placebo plus metformin (n = 19; 60.5±2.0 to 60.6±4.5cm3) and those treated with vilda-
gliptin plus metformin (n = 20; 50.4±4.1 to 51.8±4.2cm3; p = 0.20).
The intra-observer bias of pancreas volume was 0.8cm3 with a 95% limit of agreement of
9.2cm3 (p>0.05) and inter-observer bias was 8cm3 with a 95% limit of agreement of 13.1cm3
(p>0.05) (Fig 3).
Pancreas morphology
The pancreata of T2DM subjects were typically involuted, with a feathery, irregular border
when compared with age, weight and sex matched glucose tolerant controls. This is illustrated
in Fig 4. The semi-quantitative analysis of irregularity of the border of the pancreas is shown in
Fig 5. Most controls were judged to have pancreata with regular, smooth outlines (modal score
5) whereas most T2DM subjects were deemed to have an irregular pancreatic outline (modal
score 3). The distribution of scores was significantly different between T2DM and NGT sub-
jects (p<0.002; Mann-Whitney U test).
Pancreas triglyceride content
Pancreas triglyceride content was 23% higher in T2DM compared with NGT (5.4±0.3 vs.
4.4±0.4%; p = 0.02)(Fig 6), while liver triglyceride content was 6.7±0.7% in T2DM and 3.4±
0.7% in NGT (p = 0.0004) There was a positive correlation between pancreas triglyceride and
BMI in NGT (r = 0.64; p = 0.008) and whole group (r = 0.33; p = 0.08), but this was not present
in T2DM (r = 0.23; p = 0.08). There was a positive correlation between pancreas and liver tri-
glyceride in the NGT (r = 0.63; p = 0.01) but this was lost in T2DM (r = 0.02; p = 0.46), and in
the whole group (r = 0.18; p = 0.10). Liver triglyceride content has previously been reported to
be (6.7±0.7 vs. 3.4±0.8%; P<0.001) [19].
Pancreas triglyceride content remained unchanged at 6 months during placebo and metfor-
min treatment of T2DM (5.6±0.4 vs. 5.5±0.5ml; p = 0.90) and there was also no difference be-
tween the vildagliptin and metformin treated group (5.1±0.4 to 5.0±0.2%; p = 0.74).
Discussion
This study demonstrates that the mean pancreatic volume is 33% smaller in individuals with
type 2 diabetes well controlled on metformin compared to matched controls. Insulin secretion
assessed by HOMA-β was proportional to pancreas size both in T2DM and NGT groups. For
the first time the serrated boundary of the pancreas in T2DM is described. Not only is the pan-
creas small and involuted in appearance but also it has a 23% higher triglyceride content com-
pared with that of well-matched non-diabetic individuals.
The question of cause and effect is immediately posed by these data. Are people with a small
pancreas predisposed to develop T2DM, or does the pancreas decrease in volume as a conse-
quence of the ongoing pathological processes? It has been postulated that beta cell mass may be
subnormal in those predisposed to develop T2DM [26] but in the absence of a practical non-in-
vasive method of measuring this in vivo it has not been possible to pursue this hypothesis. It is
known that low birth weight is a risk factor for T2DM [27], and it may be considered that this
could be associated with a smaller pancreas. If so, this could be interpreted as indirectly sup-
porting the possibility of low pancreas volume and hence low beta cell mass as predisposing
factors for T2DM.
However, the pancreas volume could secondarily be affected by loss of normal post-meal
rise in insulin by a paracrine effect. Insulin potently stimulates growth and maintains tissue
mass at around 10-fold greater concentrations than required for metabolic effects [28].
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Fig 3. Bland-Altman plots for intra-observer (panel a) and inter-observer (panel b) analysis of
pancreas volumemeasurement (cm3). The Bland Altman statistic confirmed lack of bias and defined 95%
limits of agreeement.
doi:10.1371/journal.pone.0126825.g003
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Pancreas tissue is likely to be exposed to very high concentrations of insulin after meals, when
the local rise in concentration must vastly exceed the 10–15 fold rise achieved in plasma con-
centration [29]. When there is no local insulin production in type 1 diabetes, pancreas volume
is known to be decreased by one third [30] and this is evident within months of diagnosis [31].
In T2DM basal insulin levels are raised but there is an absence of immediate and major insulin
release after meals which could bring about growth promoting concentrations of the hormone.
There are few animal studies of pancreas volume although a study in non-human primates ob-
served a modest decrease in pancreas volume 2–6 months after inhibition of insulin secretion
by low dose streptozotocin [32].
The data presently reported establish a significant relationship between pancreas volume
and HOMA-β in both T2DM and non-diabetic groups. Further work is required to define the
precise relationship of first phase insulin response to pancreas volume. We have previously
demonstrated that acute insulin secretion in response to glucose and to arginine can be re-
turned to normal in T2DM by substantial weight loss [17] and that normal glucose regulation
is maintained for some years providing weight gain is avoided [33]. Studying larger groups of
individuals with short or long duration T2DM has established that the condition can be re-
versed in most individuals up to 10 years duration [34]. It is now feasible to test the hypothesis
that pancreas volume changes secondarily to development of the insulin secretory defect by
studying prospectively a group of subjects with short to medium duration of type 2 diabetes
over 6–12 months after restoration of normal insulin secretion and this work is underway.
Several previous studies have assessed the size of the pancreas in T2DM. A retrospective
study of individuals who had undergone an abdominal CT scan reported a small decrease in
pancreas volume in T2DM (7%; p<0.05) but the group was unusual in having a low BMI
(mean 25.4) and body weight was not matched between T2DM and non-diabetic subjects [9].
Fig 4. Comparison of the morphology of the pancreata of T2DM subjects (left) and NGT subjects
(right) demonstrating the more irregular anterior (uppermost) border of the pancreata. In the upper
panel anatomical landmarks around the pancreas have been labelledto allow interpretation of the
comparative pancreas views below.
doi:10.1371/journal.pone.0126825.g004
Fig 5. Semi-quantitive analysis of the irregularity of pancreas outline. Red: type 2 diabetes individuals;
Green: non-diabetic control individuals. Most irregular = 1 and least irregular = 5. It can be seen that most
non-diabetic individual have a smooth pancreas outline whereas many people with type 2 diabetes have an
irregular pancreas border. The distributions of scores are significantly different (p<0.002; Mann-Whitney U
test).
doi:10.1371/journal.pone.0126825.g005
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Two ultrasound studies have examined pancreas cross sectional area in type 2 diabetes. One
observed a significant 11% decrease compared with control subjects [8]. The larger ultrasound
study of 84 T2DM and 80 controls matched for age, sex and body mass observed a 22% de-
crease [35]. The recent CT study of Korean subjects with mean BMI of 25.7kg/m2 and T2DM
reported a 12–24% decrease in pancreas volume [10]. However, the abnormality has not been
widely acknowledged or discussed. The present study used a method of defined precision in
well matched groups to demonstrate a 33% decrease in pancreas volume in people with T2DM
who were well controlled on metformin therapy alone.
The association of pancreas triglyceride with T2DM remains contentious. A cross-sectional
study using ultrasound of 7,464 individuals showed higher pancreas triglyceride levels to be as-
sociated with obesity with both T2DM and pre-diabetes [36]. Magnetic resonance spectroscopy
allows measurement of intra-organ triglyceride although it relies upon accurate respiratory
triggering to acquire data solely from pancreatic tissue and not visceral fat. Using this method,
it has been shown that higher pancreas triglyceride levels are associated with raised basal insu-
lin levels, and that this relationship is present in different ethnic groups [14]. The wide scatter
of absolute levels of pancreas triglyceride with a tendency for higher levels in people with diabe-
tes has been confirmed [37]. The latter study showed that pancreas triglyceride correlated neg-
atively with early glucose-stimulated insulin secretion. Because of the danger of incorporating
visceral fat in the spectroscopic fat measurements, we developed an imaging-based method
[17] that demonstrates higher precision than spectroscopic measurements. A longitudinal
study of etiopathogenesis of T2DM using the new method has confirmed that weight-loss in-
duced decrease in pancreatic triglyceride is temporally associated with restoration of normal
glucose stimulated acute insulin secretion [17]. The present study has applied this method of
magnetic resonance imaging to characterized individuals with T2DM with good glycemic con-
trol and treated only with metformin. We have demonstrated that pancreas triglyceride content
is 23% higher than in age, weight and sex matched normal controls. Additionally, the data indi-
cate that the normal positive correlation between pancreas and liver fat is lost in T2DM. This
Fig 6. Pancreas triglyceride content in the T2DM and control group. The 23% higher triglyceride content
in the T2DM group was significant (p = 0.02; Student’s t test).
doi:10.1371/journal.pone.0126825.g006
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may be a consequence of falling plasma insulin levels during the development of T2DM [38].
This decrease would be expected to bring about decreased rates of de novo lipogenesis in the
liver and potential loss of the initial relationship between liver and pancreatic triglyceride con-
tent. Further work is required to examine this possibility.
The limitations of the present study must be considered. Firstly, MRI measurement of
organ volume has not previously been applied to the study of the pancreas in diabetes. The ac-
curacy and precision of the method applied to pancreas require to be examined. Accuracy of
such methodology compared to invasive tissue measurements is rarely established, but one
study has shown volumetry by magnetic resonance imaging to correspond almost exactly to
water displacement for pancreata of mini-pigs [39]. We demonstrate good precision as re-
flected by the Bland-Altman plots of intra- and inter-observer agreement. Additionally, repeat
measurements after 6 months were highly consistent. Thus the measurement of pancreas vol-
ume by magnetic resonance imaging can be regarded as robust. Secondly, assessment of irregu-
larity of shape of the pancreas can only be regarded as semi-quantitative and further work is
required to develop a mathematical method for measuring deviation from a smooth but vari-
able curve. Thirdly, accuracy and precision of pancreas triglyceride must be considered. Due to
the rapid enzyme-mediated autolysis of the pancreas post-mortem, data on accuracy of human
pancreas triglyceride measurement is lacking. However, we have previously reported an excel-
lent inter-scan Bland-Altman coefficient [17] and the 3-point Dixon method used gives almost
identical absolute measurements of intra-pancreatic triglyceride compared to those obtained
by the centre with the largest experience of measurement using magnetic resonance spectrosco-
py [14]. Finally, the T2DM group was large for this type of detailed study. Although the group
of subjects with proven NGT was smaller, the consistency of measured outcomes within the
relatively homogenous control group allowed confident identification of the major abnormali-
ties associated with T2DM.
In summary, this study has demonstrated that in a group of T2DM individuals with good
metabolic control on metformin therapy alone the pancreas is 33% smaller in volume, is typi-
cally involuted and has raised triglyceride content compared to normal. These gross abnormal-
ities could potentially yield prognostic information. Further work must elucidate their
relationships with the pre-diabetes phase, their interaction with treatment modalities and
changes during the natural history of type 2 diabetes.
Supporting Information
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